Skip to content
Study details
Enrolling now

NO During CPB in Neonates to Reduce Risk of AKI

Children's Hospital Medical Center, Cincinnati
NCT IDNCT04216927ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

40

Study length

about 3.5 years

Ages

0.00273790700698851–0.0848751172166437

Locations

1 site in OH

About this study

This trial is testing whether giving nitric oxide during cardiopulmonary bypass (CPB) can help prevent acute kidney injury (AKI) in newborns with congenital heart defects who are undergoing surgery. The goal is to see if this treatment reduces the risk of AKI after surgery.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Nitric Oxide
  • 2.Take Oxygen
PhasePhase 3
DrugNitric Oxide

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low9%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

nitric oxide, oxygen

Endpoints

Secondary: Biomarker evidence of AKI - IL-18, Biomarker evidence of AKI - KIM-1, Biomarker evidence of AKI - L-FABP, Biomarker evidence of AKI - NGAL, Biomarker evidence of AKI - urinary nitrite

Body systems

Cardiology / Heart